Successful Engraftment with Fludarabine, Cyclophosphamide, and Thymoglobulin Conditioning Regimen in Unrelated Transplantation for Severe Aplastic Anemia: A Phase II Prospective Multicenter Study

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 11, 2010, Pages 1582-1588

  Kang, Hyoung Jin ^a   Shin, Hee Young ^a   Park, Jun Eun ^b   Chung, Nak Gyun ^c   Cho, Bin ^c   Kim, Hack Ki ^c   Kim, Sun Young ^d   Lee, Young Ho ^e   Lim, Young Tak ^f   Yoo, Keon Hee ^g   Sung, Ki Woong ^g   Koo, Hong Hoe ^g   Im, Ho Joon ^h   Seo, Jong Jin ^h   Park, Sang Kyu ^h   Ahn, Hyo Seop ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Chungnam National University College of Medicine   (South Korea)

^e Hanyang University College of Medicine   (South Korea)

^f Pusan National University School of Medicine   (South Korea)

^g Sungkyunkwan University School of Medicine   (South Korea)

^h University of Ulsan College of Medicine   (South Korea)

Author keywords

Cyclophosphamide; Fludarabine; Severe aplastic anemia; Thymoglobulin; Unrelated donor

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; MESNA; METHOTREXATE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APLASTIC ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW TRANSPLANTATION; CATHETER INFECTION; CHILD; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; DESQUAMATION; DIARRHEA; DISEASE SEVERITY; DRUG ERUPTION; DYSPNEA; ENGRAFTMENT; ENTERITIS; ERYTHROCYTE; FEBRILE NEUTROPENIA; FEMALE; GRAFT VERSUS HOST REACTION; HEART INFARCTION; HEMATURIA; HEMORRHAGIC CYSTITIS; HUMAN; LOW DRUG DOSE; LUNG INFILTRATE; LYMPHOPROLIFERATIVE DISEASE; MALE; MORTALITY; MULTICENTER STUDY; PERICARDIAL EFFUSION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRESCHOOL CHILD; PROPHYLAXIS; PROTEINURIA; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SCHOOL CHILD; SEIZURE; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; VEIN OCCLUSION; VOMITING; WEIGHT GAIN;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; ANTIBODIES, MONOCLONAL; BONE MARROW TRANSPLANTATION; CELL COUNT; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; CYTOMEGALOVIRUS INFECTIONS; ERYTHROCYTE TRANSFUSION; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LEUKOCYTE COUNT; LYMPHOPROLIFERATIVE DISORDERS; MALE; MYELOABLATIVE AGONISTS; NEUTROPHILS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; VIDARABINE; YOUNG ADULT;

EID: 77957751201     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.05.010     Document Type: Article

References (37)

1. Storb R., Etzioni R., Anasetti C., et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994, 84:941-949.
2. Champlin R.E., Perez W.S., Passweg J.R., et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 2007, 109:4582-4585.
3. Deeg H.J., Anasetti C., Petersdorf E., et al. Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matched unrelated donors. Blood 1994, 83:3417-3418.
4. Deeg H.J., Amylon I.D., Harris R.E., et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 2001, 7:208-215.
5. Deeg H.J., O'Donnell M., Tolar J., et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 2006, 108:1485-1491.
6. Bacigalupo A., Locatelli F., Lanino E., et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant 2005, 36:947-950.
7. Remberger M., Svahn B.M., Hentschke P., Lofgren C., Ringden O. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999, 24:823-830.
8. Zuckermann A.O., Grimm M., Czerny M., et al. Improved long-term results with thymoglobuline induction therapy after cardiac transplantation: a comparison of two different rabbit-antithymocyte globulines. Transplantation 2000, 69:1890-1898.
9. Hardinger K.L., Rhee S., Buchanan P., et al. A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation 2008, 86:947-952.
10. Kang H.J., Shin H.Y., Choi H.S., Ahn H.S. Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia. Bone Marrow Transplant 2004, 34:939-943.
11. Bacigalupo A., Oneto R., Lamparelli T., et al. Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG). Bone Marrow Transplant 2001, 28:1093-1096.
12. Bacigalupo A., Lamparelli T., Milone G., et al. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants. Bone Marrow Transplant 2010, 45:385-391.
13. Georges G.E., Storb R. Allogeneic hematopoietic cell transplantation for aplastic anemia. Thomas' Hematopoietic Cell Transplantation 2004, 981-1001. Blackwell Publishing Ltd, Oxford. K.G. Blume, S.J. Forman, F.R. Appelbaum (Eds.).
14. Fuhrer M. Risk-adapted procedures for HSCT from alternative donor in children with severe aplastic anaemia. Bone Marrow Transplant 2008, 42(Suppl 2):S97-S100.
15. Kojima S., Inaba J., Yoshimi A., et al. Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation. Br J Haematol 2001, 114:706-711.
16. Vassiliou G.S., Webb D.K., Pamphilon D., Knapper S., Veys P.A. Improved outcome of alternative donor bone marrow transplantation in children with severe aplastic anaemia using a conditioning regimen containing low-dose total body irradiation, cyclophosphamide and Campath. Br J Haematol 2001, 114:701-705.
17. Kim S.Y., Lee J.W., Lim J., et al. Unrelated donor bone marrow transplants for severe aplastic anemia with conditioning using total body irradiation and cyclophosphamide. Biol Blood Marrow Transplant 2007, 13:863-870.
18. Peinemann F., Grouven U., Kroger N., Pittler M., Zschorlich B., Lange S. Unrelated donor stem cell transplantation in acquired severe aplastic anemia: a systematic review. Haematologica 2009, 94:1732-1742.
19. Eapen M., Ramsay N.K., Mertens A.C., Robison L.L., DeFor T., Davies S.M. Late outcomes after bone marrow transplant for aplastic anaemia. Br J Haematol 2000, 111:754-760.
20. Sanders J.E. Chronic graft-versus-host disease and late effects after hematopoietic stem cell transplantation. Int J Hematol 2002, 76(Suppl 2):15-28.
21. Socie G., Henry-Amar M., Cosset J.M., Devergie A., Girinsky T., Gluckman E. Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia. Blood 1991, 78:277-279.
22. Socie G., Henry-Amar M., Bacigalupo A., et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med 1993, 329:1152-1157.
23. Chan K.W., Li C.K., Worth L.L., et al. A fludarabine-based conditioning regimen for severe aplastic anemia. Bone Marrow Transplant 2001, 27:125-128.
24. Kumar R., Prem S., Mahapatra M., et al. Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia. Bone Marrow Transplant 2006, 37:745-749.
25. Novitzky N., Thomas V., du Toit C., McDonald A. Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD. Bone Marrow Transplant 2009, 43:779-785.
26. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001, 98:2942-2947.
27. Remberger M., Storer B., Ringden O., Anasetti C. Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 2002, 29:391-397.
28. Schrezenmeier H., Passweg J.R., Marsh J.C., et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007, 110:1397-1400.
29. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000, 96:2062-2068.
30. Yagasaki H., Kojima S., Yabe H., et al. Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis. Biol Blood Marrow Transplant 2009, 15:1603-1608.
31. Kennedy-Nasser A.A., Leung K.S., Mahajan A., et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant 2006, 12:1277-1284.
32. Maury S., Balere-Appert M.L., Chir Z., et al. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. Haematologica 2007, 92:589-596.
33. Locasciulli A., Oneto R., Bacigalupo A., et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2007, 92:11-18.
34. Champlin R.E., Horowitz M.M., van Bekkum D.W., et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 1989, 73:606-613.
35. Gajewski J.L., Johnson V.V., Sandler S.G., Sayegh A., Klumpp T.R. A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. Blood 2008, 112:3036-3047.
36. Armand P., Kim H.T., Cutler C.S., et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007, 109:4586-4588.
37. Lee J.W., Kang H.J., Kim E.K., Kim H., Shin H.Y., Ahn H.S. Effect of iron overload and iron-chelating therapy on allogeneic hematopoietic SCT in children. Bone Marrow Transplant 2009, 44:793-797.